Great to see such encouraging interim headline results for efficacy of the Pfizer and Moderna vaccines! With what is admittedly the great benefit of hindsight - apparently it would have been better to randomise between active and placebo groups in a ratio of say 2:1 rather than 1:1. Better for participants in terms of chance of getting protected earlier. Also each trial would have reached its preset criterion of n total events, triggering analysis, more rapidly that way. Ironically, in each trial the interim analysis would have been triggered earlier had the vaccine been less effective!
1 Like
Prof Newcombe, do you use twitter? i ask because Prof Harrell pointed to some posts re COVID by Stephen Senn on twitter, found at the top here: http://www.senns.uk/Blogs.html Senn has that industry perspective which is useful here…
1 Like
Not sure I understand why the interim analysis would have been earlier with more subjects on the active arm where the event rate was lower.